A Safety Study of Balsamic Bactrim in Pediatric Participants With Acute Bronchitis

  • Respiratory Disorder
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:


This trial runs in
  • Peru
Trial Identifier:

NCT02879981 ML30017

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This pilot, multicentric and observational study will assess the safety of sulfamethoxazole + trimethoprim + guaifenesin (Balsamic Bactrim) in pediatric participants with acute bronchitis. Administration of treatment will be according to treating physician's recommendation under local labeling.

      Hoffmann-La Roche Sponsor
      NCT02879981,ML30017 Trial Identifier
      Guaifenesin, Sulfamethoxazole, Trimethoprim Treatments
      Bronchitis Condition
      Official Title

      A Pilot, Multicentric and Observational Study of Safety of Sulfamethoxazole + Trimethoprim + Guaifenesin (Balsamic Bactrim) in Pediatric Patients With Acute Bronchitis

      Eligibility Criteria

      All Gender
      ≥ 4 Years & ≤ 14 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Participants starting treatment with Bactrim Balsamic suspension
      • Participants with a clinical diagnosis of acute bronchitis (cough with or without sputum production less than 30 days) according to the medical criteria
      Exclusion Criteria
      • Participants who have started treatment with another antibiotic at the time of the visit
      • Participants with no respiratory infections
      • Participants with mental disorders that do not permit the clinical evaluation of the participant according to the treating physician's criteria
      • Participants with severe hepatic parenchymal damage
      • Participants with severe renal failure making it difficult to monitor drug plasma concentration
      • Participants with hypersensitivity to any of Balsamic Bactrim active ingredients, excipients, and/or sulfas

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now